The immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) is expressed by a subset of murine plasmacytoid DCs (pDCs) in tumor-draining LNs, where it can potently activate Foxp3 
Introduction

Regulatory T cells (Tregs) represent a critical barrier to immunotherapy of tumors.
Established tumors suppress immune responses against their own antigens, and Tregs are emerging as a key mechanism contributing to this state of functional unresponsiveness 1 . In murine models, host Tregs become activated within days of tumor implantation 2 . Once activated, Tregs are difficult to eliminate, and serve to potently and dominantly inhibit otherwise
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We have shown that Foxp3 + Tregs in the draining lymph nodes of mouse tumors become highly activated by exposure to the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) 4, 5 . In tumor-draining lymph nodes (TDLNs), IDO is expressed by a specific subset of IDO-competent plasmacytoid DCs 6 . The combination of these IDO-expressing pDCs and IDOactivated Tregs renders the local milieu in the TDLN profoundly inhibitory for T cell activation 7 .
Tregs can be suppressive, but this is not a fixed and immutable attribute. Resting Tregs are not spontaneously suppressive, and require an activation step before they become functionally inhibitory 8 . Conversely, the suppressive phenotype of Tregs is plastic. When
Foxp3 is artificially ablated in mature Tregs, the suppressor phenotype is converted to a proinflammatory, T helper-like phenotype that can participate in autoimmunity 9 . Likewise, Tregs exposed to certain inflammatory signals (e.g., from activated DCs or TLR ligands) can lose their suppressor activity 10 , and may alter their phenotype (be "re-programmed") to resemble proinflammatory effector cells [11] [12] [13] . Thus, at least in these experimental models, Tregs show a significant degree of phenotypic plasticity, and are susceptible to both activation and de-activation (reprogramming) by signals from their local microenvironment.
However, it is not known whether this apparent plasticity of Tregs is of biologic relevance for tumor immunology. In the current study we test the hypothesis that, under conditions of antigen-driven T cell response to tumors, IDO functions as a critical molecular "switch" in tumor-draining LNs, regulating the phenotype and functional activity of Tregs. We show that when IDO is active, Tregs are maintained in their normal potently suppressive state; but when IDO is blocked, Tregs undergo an inflammation-induced, IL-6-dependent conversion into a non-suppressive, proinflammatory phenotype similar to TH17 cells. These findings 
METHODS
Reagents, cell lines and mouse strains
A complete list of reagents, 1MT preparation, tumor cell lines and all transgenic and knockout mouse strains is given in Supplemental on-line materials. Animal studies were approved by the Institutional Animal Care and Use Committee of the Medical College of Georgia. Details of are included in Supplemental on-line materials.
Tumors
Tumor implantation and harvesting of TDLNs are described in detail in ref. 4 . A large inoculum of B16F10 and B16-OVA tumor cells was used (1×10 6 ) to ensure that established tumors rapidly drove Treg activation and suppression in the TDLN. Tumor area was measured at necropsy on day 11 as the product of orthogonal diameters; or was measured serially 3×/week.
Vaccines
Details of the vaccine preparations are given in Supplemental on-line materials.
Aadoptive transfer
For OT-I adoptive transfer, mice received 2×10 6 sorted CD8 + OT-I spleen cells i.v 4 . For Treg adoptive transfer, Tregs were isolated from spleens of TCR-tg OT-II mice bred onto the Foxp3 GFP (Thy1.1-congenic) background 14 , and FACS-sorted as CD4 + GFP + cells.
OT-II Foxp3-GFP Thy1.1 Tregs (1×10 6 ) were mixed with OT-I cells for co-adoptive transfer.
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Treg activation co-cultures and readout assays
The Treg culture system has been described in detail 4 , and complete methods are given in 
FACS staining
For intracellular cytokine staining, cells were harvested from co-cultures, or isolated from mechanically disaggregated TDLNs ex vivo, and incubated for 4 hrs with 5 ng/ml PMA + 2 uM ionomycin 15 in the presence of brefeldin A (GolgiPlug, BD Bioscience), then fixed in Cytoperm/Cytofix (BD Bioscience) on ice and stained in BD Permwash solution per the manufacturer's instructions. For tumor-disaggregation studies, tumors were treated for 1 hr with 1 mg/ml collagenase (Sigma C5138), 0.1 mg/ml DNAse (Sigma D5025) and 0.1 mg/ml hyaluronidase (Sigma H3884) in RPMI 1640 medium.
IDO-transfected TREX cells and western blot
Detailed methods are given in Supplemental Materials online.
Statistical analysis
Multiple treatment groups were compared by ANOVA with Tukey's HSD test.
RESULTS
IDO plus effector T cells activate Foxp3 + Tregs for suppression
In vitro studies were performed using the co-culture system shown in Figure 1A For personal use only. on September 14, 2017. by guest www.bloodjournal.org From -6 -(described in Methods, from ref. 4 ). Resting Tregs were sorted from spleens of B6 mice without tumors. IDO-expressing pDCs were enriched from the TDLNs of mice with B16 melanoma tumors. As a source of activated effector T cells, OVA-specific OT-I T cells (sorted CD8 + ) were added to co-cultures with cognate OVA peptide antigen. After 2 days, Tregs were recovered from co-cultures by FACS sorting and tested for suppressor activity in a readout assay comprising allogeneic A1 T cells (TCR-tg, recognizing a peptide of HY) plus congenic CBA spleen DCs. Figure 1A shows that IDO-activated Tregs acquired efficient suppressor activity, comparable to the most potent suppression reported in the literature 16, 17 , and an order of magnitude more efficient on a per-cell basis than the same Tregs activated using anti-CD3
antibodies plus recombinant IL-2 ( Figure 1A ). (For CD3-induced activation, IDO was blocked by adding the IDO-inhibitor 1-methyl-D-tryptophan, 1MT). We have previously shown that similar IDO-induced Treg activation also occurs in vivo in TDLNs 4 .
In order for Tregs to become activated by IDO, it was also necessary for antigenactivated OT-I cells to be present. If the cognate OVA antigen for OT-I was omitted, then Tregs failed to acquire suppressor activity ( Figure 1B ). Blocking IDO with 1MT also prevented Tregs from acquiring suppressor activity ( Figure 1C ). Thus, two conditions were required for Tregs to become activated for suppression: functional IDO and activated OT-I.
In the absence of IDO, Tregs undergo conversion to a TH17-like phenotype
A key point not elucidated by the preceding experiments was the fate of those Tregs 13, 19 .)
The transcription factor RORγt is required for normal differentiation of naive CD4 + T cells along the TH17 lineage 20 . Figure 2B shows that Rorγt-null Tregs were unable to convert to IL-17 expression in our system. We next asked whether RORγt was required for the loss of functional Treg suppressor activity observed when IDO was blocked by 1MT (shown in Figure 1C ). Figure 2C shows that wild-type Tregs activated in the presence of 1MT lost all functional suppressor activity, as expected;
whereas RORγt-deficient Tregs activated under identical conditions retained significant suppressor activity, even in the presence of 1MT. Thus, the loss of suppressor activity seen when IDO was blocked by 1MT represented an active, RORγt-dependent conversion of Tregs to the TH17 phenotype, not simply a passive failure of Treg activation.
IL-17 is expressed early during TH17 differentiation, whereas IL-22 is expressed later, and is thus is a marker of an established TH17 phenotype 22 . Figure 2D shows 4-color staining of cells can co-express IL-2 in vivo 24 , and TH17 cells differentiated in vitro can produce IL-2 and TNFα 25 . Figure 2E shows that, in our system, most of the re-programmed Tregs co-expressed can be produced by activated pDCs, so we asked whether pDCs from TDLNs produced IL-6 in our co-cultures ( Figure 3A ). For these studies, the feeder layers in co-cultures were depleted of macrophages (a potential contaminating source of IL-6). IL-17 upregulation in Tregs was unaffected by macrophage depletion, and essentially all of the IL-6-producing cells under these conditions were the pDCs (identified as CD11c + in the FACS plots). IL-6 was expressed only when IDO was blocked with 1MT; if IDO was enzymatically active then IL-6 was suppressed.
The suppressive effect of IDO was further confirmed by measuring IL-6 in co-culture supernatants by ELISA ( Figure 3A , right-hand panel)
To test whether IL-6 was mechanistically required for upregulation of IL-17 we used neutralizing anti-IL-6 antibody. Figure 3B shows that blocking IL-6 completely abrogated upregulation of IL-17 in Tregs in co-cultures. Consistent with a mechanistic role for IL-6, addition of exogenous recombinant IL-6 to co-cultures drove even more conversion of Tregs, such that the large majority now became converted to the TH17-like phenotype ( Figure 3C ).
IL-6 expression in pDCs is triggered by activated OT-I cells
IL-6 induction in pDCs also required a signal from activated OT-I cells, in addition to IDO blockade. Thus, if OVA antigen was omitted from co-cultures, IL-6 was not induced even in the presence of 1MT ( Figure 3D , middle panel). This suggested that antigen presentation by pDCs to OT-I might be necessary to trigger IL-6 induction. During the process of antigen presentation, it is known that CD28 and its cognate B7 counter-ligands actively cluster in the 26 ; and in other systems, CD28-mediated engagement of B7 can generate an intracellular "reverse" signal in DCs that triggers IL-6 production 27 . Therefore, we asked whether the requirement OVA antigen in our system could be replaced by artificially crosslinking B7 molecules, using a recombinant CD28-Ig fusion protein, as described by others 27 . Figure 3D , right panel, shows that CD28-Ig was able to fully substitute for the OVA signal, both for IL-6 induction in the pDCs, and for driving IL-17 and IL-22 upregulation in Tregs. These findings were thus consistent with a model (diagrammed in Figure 3D ) in which antigenactivated OT-I delivered an IL-6-inducing signal to pDCs via CD28-mediated engagement of B7 molecules.
IDO suppresses expression of IL-6 in pDCs
Figure 3A had shown that IL-6 was produced by pDCs only when IDO was blocked by
1MT. This suggested that the IDO in pDCs might actively suppress their own production of IL-6. (We have previously demonstrated such an autocrine/paracrine effect of IDO on type I interferon production by pDCs 28 .) IDO depletes the amino acid tryptophan, which can activate the amino-acid sensitive GCN2-kinase pathway, as diagrammed in Figure 4A 4 . Activated GCN2
phosphorylates ribosomal eIF2α, which alters translation of target mRNAs. One mRNA species known to be sensitive to amino-acid induced regulation is the transcription factor NF-IL6
(C/EBPβ), which is a key regulator of IL-6 gene transcription 29 . Therefore, we asked whether IDO blocked IL-6 production by activating the GCN2 pathway in pDCs.
B16 tumors were grown in WT B6 mice, or in mice lacking IDO1 (IDO1-KO) or GCN2
(GCN2-KO). pDCs from TDLNs were used as APCs in activation co-cultures (the Tregs and other cells in co-culture were all from WT mice). Figure 4B shows that pDCs lacking IDO1
were unable to suppress their own IL-6 production in co-cultures (i.e., even without 1MT, IL-6
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The NF-IL-6 (C/EBPβ) transcription factor exists in two forms: transcriptionally-active LAP (Liver-enriched transcriptional Activator Protein) isoforms that promote IL-6 transcription, and the dominant-negative LIP (Liver Inhibitory Protein) which inhibits LAP. Both LIP and LAP are generated from the same mRNA via alternate ribosomal start sites 29 . GCN2 kinase is known to alter ribosomal initiation of many mRNA species 30 . Therefore, we asked whether the IDO→GCN2 pathway might up-regulate the dominantly-inhibitory LIP isoforms of NF-IL6.
These mechanistic studies could not be performed on the tiny number of primary pDCs from TDLNs, so we used a model of T-REX cells transfected with a doxycycline-inducible IDO cDNA construct. Figure 4D shows that induction of the IDO gene triggered up-regulation of the inhibitory LIP isoform of NF-IL6, and that this was blocked by two different functional inhibitors of IDO enzymatic activity. Thus, taken together, our data are consistent with the hypothesis that IDO directly suppresses IL-6 induction, via GCN2-mediated regulation of NF-IL6. shown in the fourth panel in Figure 5A ). In all groups, the total percentage of but qualitatively the expression of IL-6 was confined to the pDCs.)
Replacement of Foxp3 + Tregs by TH17-like cells in vivo
Direct conversion of mature Foxp3 + Tregs to TH17-like cells in vivo
In Figure 5A , the presence of residual Foxp3 GFP fluorescence in essentially all of the Figure 5C ). The transferred Tregs were isolated from TCR-tg OT-II mice (CD4 + , specific for a peptide of ovalbumin) that had been crossed with Foxp3 GFP mice, and bred on a Thy1.1 congenic background (described in Methods). OT-II Foxp3-GFP Thy1.1 Tregs were sorted as CD4 + GFP + cells, and thus were known to be uniformly Foxp3 + at the time of transfer. Figure 5C shows that in control recipients (without vaccination or 1MT), none of the transferred Figure 5D shows that upregulation of IL-17 by Tregs in TDLNs also required an intact RORγt transcription factor in the Tregs (consistent with the in vitro model shown in Figure 2B ).
For these studies, the tumor-bearing hosts were bone-marrow chimeras of RORγt null marrow transplanted into wt B6 hosts, since the RORγt-deficient mice themselves are defective in peripheral LN development 21 .
For Figure 5A ). When followed for a longer period, tumors treated with 1MT plus OT-I and vaccine showed sustained growth delay ( Figure 6B ).
Treg conversion can be driven by endogenous T cells against a shared self/tumor antigen
The OVA system was informative for mechanistic studies, but a more realistic clinical scenario is vaccination against a shared self/tumor antigen to which the host is already tolerant. Under these conditions, it was not clear whether there would be adequate endogenous CD8 + T cell response to drive conversion of Tregs to TH17-like cells. To test this, we used an altered peptide ligand sequence developed against the melanoma-associated antigen TRP1, optimized to break Figure 6D ). As in the B16-OVA experiments, a large inoculum of B16F10 tumor cells (1×10 6 ) and an early time-point were used; under these stringent conditions, vaccine and 1MT
were each minimally effective as single agents, but the combination of vaccine+1MT showed significant synergistic anti-tumor effect.
1MT enhances response to CpG-based vaccine
To confirm that the effect of 1MT was not restricted only to lentivector vaccines, we tested 1MT with a vaccine comprising OVA protein emulsified in incomplete Freund's adjuvant plus CpG oligodeoxynucleotide 1826, a TLR9 ligand 37 . Figure 7A shows that this vaccine by itself had only modest effect against established (day 7) B16-OVA tumors, but that the addition of 1MT showed significant synergy with vaccine. When similar studies were performed in RORγt-null bone-marrow chimeric mice (RORγt-null marrow→B6 hosts, as in Figure 5D ), the synergistic effect of 1MT was preserved, indicating that the RORγt/IL-17 pathway itself was not . In these mice, the synergistic effect of 1MT was completely abrogated ( Figure 7A) . Thus, the helper activity of CD4 + cells appeared required for the synergistic effect of 1MT.
In the tumors themselves, CFSE-labeled OT-I cells showed better ability to divide and upregulate differentiation markers (granzyme B and CXCR3) in mice treated with 1MT+vaccine, The CD4 + T cell lineage is emerging as more plastic than previously thought 40 . In the A key finding from our study is that signals from activated effector T cells were strictly required to drive conversion of Tregs to TH17-like cells when IDO was blocked. In vitro, this was shown by the obligate requirement for antigen-activated OT-I in order to upregulate IL-6 in pDCs, and to drive conversion of Tregs. The signal supplied by antigen could be replaced by artificial ligation of B7 molecules using CD28-Ig fusion protein, suggesting that the role of activated OT-I was to provide a CD28→B7 mediated intracellular signal to the pDCs. This is consistent with the previously described role of CD28→B7 signaling as an inducer of IL-6 in other models 27, 46 . In vivo, OVA-activated OT-I cells could drive conversion of Tregs in TDLNs of OVA-expressing tumors. Importantly, however, conversion of Tregs could also be driven by a vaccine against TRP1 (a shared self/tumor antigen) when combined with 1MT. For these studies we used an immunogenic mutated TRP1 peptide capable of breaking tolerance to the native TRP1 protein 34 , delivered in a lentivirus vaccine vector that stimulates robust CD8 + T cell responses 35, 36 . The efficacy of this vaccine in driving Treg conversion when combined with 1MT is an important finding, because it means that Treg conversion could be driven by the natural frequency of T cells against an endogenous self/tumor antigen, as long as IDO was blocked.
In our system, conversion of Tregs to TH17-like cells required IL-6. IL-6 has been implicated in abrogation of Treg suppression in a variety of experimental models 10, 11, 19 .
Although other cytokines may also serve to bias cells toward the TH17 phenotype 13, 47 , neutralizing-antibody studies showed that IL-6 was strictly required in our system. In turn, IL-6 expression was regulated by IDO, such that when IDO was active, production of IL-6 was suppressed. Thus, we hypothesize that a key molecular mechanism by which IDO maintains For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
